Published in Lancet on February 27, 1988
Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Malar J (2013) 0.93
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs. Malar J (2013) 0.91
Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal. Bull World Health Organ (1992) 0.90
Tropical medicine. Postgrad Med J (1991) 0.77
DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell (2001) 2.69
Analysis of pfmdr1 and drug susceptibility in fresh isolates of Plasmodium falciparum from subsaharan Africa. Mol Biochem Parasitol (1995) 2.29
Dimerization of HIV-1Lai RNA at low ionic strength. An autocomplementary sequence in the 5' leader region is evidenced by an antisense oligonucleotide. J Biol Chem (1995) 2.26
HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet (1994) 2.25
env sequences of simian immunodeficiency viruses from chimpanzees in Cameroon are strongly related to those of human immunodeficiency virus group N from the same geographic area. J Virol (2000) 2.17
Genetic diversity and HIV detection by polymerase chain reaction. Lancet (1995) 2.03
Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol (1995) 1.99
Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan real-time PCR assay. J Clin Microbiol (2001) 1.97
Wild Mandrillus sphinx are carriers of two types of lentivirus. J Virol (2001) 1.96
Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. JAMA (1996) 1.94
Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood (1995) 1.83
Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU. Chest (1998) 1.75
Structural brain changes in tinnitus. Cereb Cortex (2005) 1.71
Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium falciparum. Mol Biochem Parasitol (1995) 1.71
In vitro study of drug sensitivity of Plasmodium falciparum: evaluation of a new semi-micro test. Am J Trop Med Hyg (1983) 1.69
Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol (1997) 1.64
Destructive arthropathy in chondrocalcinosis articularis. Arthritis Rheum (1976) 1.63
Effect of indinavir on HIV-related wasting. AIDS (1998) 1.59
In vitro activity of artemisinin derivatives against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1993) 1.57
In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum. Antimicrob Agents Chemother (1994) 1.55
Detection of diverse variants of human immunodeficiency virus-1 groups M, N, and O and simian immunodeficiency viruses from chimpanzees by using generic pol and env primer pairs. J Infect Dis (2000) 1.52
Desipramine or cyproheptadine for reversing chloroquine resistance? Lancet (1990) 1.52
Plasmodium falciparum and Plasmodium vivax: lactate dehydrogenase activity and its application for in vitro drug susceptibility assay. Exp Parasitol (1995) 1.51
Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS. AIDS (1997) 1.51
Lymphadenopathy-associated virus type 2 in AIDS and AIDS-related complex. Clinical and virological features in four patients. Lancet (1987) 1.49
Parasite virulence factors during falciparum malaria: rosetting, cytoadherence, and modulation of cytoadherence by cytokines. Infect Immun (1993) 1.48
Plasmodium falciparum: molecular characterization of multidrug-resistant Cambodian isolates. Exp Parasitol (1996) 1.48
NMR evidence for gapped spin excitations in metallic carbon nanotubes. Phys Rev Lett (2005) 1.44
Lack of screening test sensitivity during HIV-1 non-subtype B seroconversions. AIDS (1996) 1.42
Cholangiopathy associated with Microsporidia infection of the common bile duct mucosa in a patient with HIV infection. Ann Intern Med (1992) 1.41
Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet (1991) 1.41
HIV-1 group O infection in Cameroon, 1986 to 1998. Emerg Infect Dis (2001) 1.41
HIV-1 subtypes and plasma RNA quantification. AIDS (1999) 1.40
Variability of human immunodeficiency virus type 2 (hiv-2) infecting patients living in france. Virology (2001) 1.40
[Tuberculous meningitis in adults. On clinical, biological, and current therapeutic aspects. Apropos of 58 recent cases]. Presse Med (1969) 1.39
HFRS after a wild rodent bite in the Haute-Savoie--and risk of exposure to Hantaan-like virus in a Paris laboratory. Lancet (1984) 1.38
Observation of an antimatter hypernucleus. Science (2010) 1.38
Lymphoma and Epstein-Barr virus DNA in blood during interleukin-2 therapy in antiretroviral-naïve HIV-1-infected patients: a substudy of the ANRS 119 trial. HIV Med (2013) 1.38
[Plasmodium falciparum malaria: type R1 resistance to quinine in west Africa]. Presse Med (1998) 1.38
Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum. Mol Biochem Parasitol (2001) 1.36
In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Antimicrob Agents Chemother (1999) 1.35
Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group. N Engl J Med (1993) 1.35
Phylogenetic analysis of 49 newly derived HIV-1 group O strains: high viral diversity but no group M-like subtype structure. Virology (2002) 1.34
Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS (1998) 1.33
Serological and virological characterization of HIV-1 group O infection in Cameroon. AIDS (1997) 1.33
Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol (2005) 1.29
Imported human African trypanosomiasis in Europe, 2005-2009. Euro Surveill (2009) 1.28
Varicella in patients infected with the human immunodeficiency virus. Arch Dermatol (1990) 1.28
In vitro activity of pyrimethamine, cycloguanil, and other antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1994) 1.28
Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. J Virol (1998) 1.27
Surveillance of listeria infections in Europe. Euro Surveill (2005) 1.26
[Destructive arthropathies in chondrocalcinosis]. Rev Rhum Mal Osteoartic (1973) 1.26
Dengue type 3 virus infections in European travellers returning from the Comoros and Zanzibar, February-April 2010. Euro Surveill (2010) 1.22
Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet (1988) 1.21
In vitro susceptibility of Cambodian isolates of Plasmodium falciparum to halofantrine, pyronaridine and artemisinin derivatives. Ann Trop Med Parasitol (1994) 1.21
HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network. AIDS (2000) 1.21
First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Euro Surveill (2015) 1.20
[Plasmodium falciparum: interpretation of the semi-microtest of in vitro chemosensitivity by H3-hypoxanthine incorporation]. Pathol Biol (Paris) (1984) 1.20
Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR. J Clin Microbiol (2001) 1.19
In vitro activity of the enantiomers of mefloquine, halofantrine and enpiroline against Plasmodium falciparum. Br J Clin Pharmacol (1992) 1.19
[The unexpected Chikungunya outbreak]. Rev Med Interne (2006) 1.17
Ezrin-radixin-moesin-binding phosphoprotein 50 is expressed at the apical membrane of rat liver epithelia. Hepatology (2001) 1.16
Blood levels and in vitro activity of desethylchloroquine against Plasmodium falciparum. Lancet (1984) 1.16
Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol (1987) 1.15
In vitro activity of halofantrine and its relationship to other standard antimalarial drugs against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1992) 1.13
Presence of HIV-1 in human parenchymal and non-parenchymal liver cells in vivo. J Hepatol (1993) 1.12
Respiratory frequencies of sleeping infants during the first months of life: correlations between values in different sleep states. Early Hum Dev (1981) 1.12
HIV-1 group N among HIV-1-seropositive individuals in Cameroon. AIDS (2000) 1.12
Reversal of chloroquine resistance with desipramine in isolates of Plasmodium falciparum from Central and West Africa. Trans R Soc Trop Med Hyg (1991) 1.12
Shortening of the diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods (2000) 1.10
Screening for hepatitis A antibody before prescribing standard immunoglobulin for Europeans staying in tropical areas. Lancet (1984) 1.09
PRRT2 mutations and paroxysmal disorders. Eur J Neurol (2013) 1.08
Substrate specificity of the Ogg1 protein of Saccharomyces cerevisiae: excision of guanine lesions produced in DNA by ionizing radiation- or hydrogen peroxide/metal ion-generated free radicals. Nucleic Acids Res (1998) 1.07
HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS (1997) 1.07
Severe chloroquine-resistant falciparum malaria in Gabon with decreased sensitivity to quinine. Trans R Soc Trop Med Hyg (1986) 1.07
Clinical characteristics of the smooth tubercle bacilli 'Mycobacterium canettii' infection suggest the existence of an environmental reservoir. Clin Microbiol Infect (2010) 1.06
Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells. Hum Pathol (1990) 1.06
Unreliability of Dill Glazko test in detecting chloroquine in urine. Lancet (1985) 1.06
Chloroquine-resistant falciparum malaria in Benin. Lancet (1986) 1.06
Precision measurement of charged pion and kaon differential cross sections in e+ e- annihilation at sqrt[s]=10.52 GeV. Phys Rev Lett (2013) 1.06
Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. J Infect Dis (1995) 1.04
Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis (1993) 1.04
Fatal acute melioidosis in a tourist returning from Martinique Island, November 2010. Euro Surveill (2011) 1.04
Use of molecular beacons to detect an antifolate resistance-associated mutation in Plasmodium falciparum. Antimicrob Agents Chemother (2000) 1.04
In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg (1993) 1.02
Correlation of CD8 lymphocyte activation with cellular viremia and plasma HIV RNA levels in asymptomatic patients infected by human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1996) 1.02
Plasmodium falciparum: detection of P-glycoprotein in chloroquine-susceptible and chloroquine-resistant clones and isolates. Exp Parasitol (1995) 1.02
HIV-1 detection in cervicovaginal secretions during pregnancy. AIDS (1997) 1.01
HIV-1 group O sensitivity to antiretroviral drugs. AIDS (1995) 1.01
High Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine in Harper, Liberia: results in vivo and analysis of point mutations. Trans R Soc Trop Med Hyg (2003) 1.01
Study of e+ e- → π+ π- J/ψ and observation of a charged charmoniumlike state at Belle. Phys Rev Lett (2013) 1.01
Chloroquine uptake by Plasmodium falciparum-infected human erythrocytes during in vitro culture and its relationship to chloroquine resistance. Antimicrob Agents Chemother (1985) 1.01
Plasmodium falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion. Exp Parasitol (1995) 1.00
Chloroquine-potentiating action of antihistaminics in Plasmodium falciparum in vitro. Ann Trop Med Parasitol (1991) 1.00
Vertical transmission of HIV-2. Lancet (1990) 1.00
Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother (1996) 0.99